poisar

Stocks · News reference

Adial Pharmaceuticals Says As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting; Anticipates Matthew Davidson To Be Appointed President And CEO; Anticipates Termination Of CFO Vinay Shah After 2026 Annual Meeting; Anticipates Board Changes And Legacy Member Resignations

Benzinga Newsdesk

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As of August 10, 2026, Adial Pharmaceuticals, Inc. (the

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ADIL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Na

    Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    Adial Pharmaceuticals granted 155,446 stock options to a new employee at an exercise price of $4.22 per share as an inducement to employment. The options vest over four years and have a ten-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4). Following its June 2026 acquisition of Azora Therapeutics, Adial has shifted focus to treating inflammatory diseases, with AT177 as its lead program for ulcerative colitis treatment, currently in IND-enabling studies with an IND filing planned for H1 2027.

    ADIL